LEXINGTON, Mass.--( BUSINESS WIRE )--Agenus Inc. (NASDAQ: AGEN), an immunology company developing innovative treatments for cancers and other diseases, will release its second quarter 2015 financial results before the market opens on Thursday, July 23, 2015.

LEXINGTON, Mass.--( BUSINESS WIRE )--Agenus Inc. (NASDAQ: AGEN), an immunology company developing innovative treatments for cancers and other diseases, invites investors and the general public to its Annual Meeting of Stockholders to begin at 5:00 p.m. ET on Wednesday, June 24, 2015.

LEXINGTON, Mass.--( BUSINESS WIRE )--Agenus Inc. (NASDAQ: AGEN), an immunology company developing innovative treatments for cancers and other diseases, today announced that the Company will present at the 2015 JMP Securities Life Sciences Conference on Tuesday, June 23 rd  at 12:00 p.m.

LEXINGTON, Mass.--( BUSINESS WIRE )--Agenus Inc. (NASDAQ: AGEN), an immunology company developing innovative treatments for cancers and other diseases, today announced the appointment of C. Evan Ballantyne as the Company’s Chief Financial Officer, effective immediately. Mr.

Collaboration involves two proprietary Merck targets LEXINGTON, Mass.--( BUSINESS WIRE )--Agenus Inc. (NASDAQ: AGEN), an immunology company developing innovative treatments for cancers and other diseases, announced today that Merck, known as MSD outside the United States and Canada, through a

Most significant improvements seen in patients with less elevated PD-L1 expression in peripheral blood Improvement in overall survival seen independent of MGMT methylation status LEXINGTON, Mass.--( BUSINESS WIRE )--Agenus Inc. (NASDAQ:AGEN), an immunology company developing innovative treatments

LEXINGTON, Mass.--( BUSINESS WIRE )--Agenus Inc. (NASDAQ: AGEN), an immunology company developing innovative treatments for cancers and other diseases, today announced that the Company will present at the Jefferies 2015 Healthcare Conference on Thursday, June 4 th  at 1:00 p.m. Eastern Time.

LEXINGTON, Mass.--( BUSINESS WIRE )--Agenus Inc. (NASDAQ: AGEN), an immunology company developing innovative treatments for cancers and other diseases, today announced the closing of its public offering of 12,650,000 shares of common stock, offered at a price to the public of $6.30 per share, which

LEXINGTON, Mass.--( BUSINESS WIRE )--Agenus Inc. (NASDAQ: AGEN), an immunotherapy company developing immune-oncology checkpoint modulators (CPMs), heat shock protein peptide-based vaccines and immune adjuvants, today announced that it intends to offer and sell, subject to market conditions, shares

LEXINGTON, Mass.--( BUSINESS WIRE )--Agenus Inc. (NASDAQ: AGEN), an immunology company developing innovative treatments for cancers and other diseases, today announced the pricing of an underwritten public offering of 11,000,000 shares of its common stock at a price to the public of $6.30 per

Improved median Overall Survival and Progression Free Survival observed for Prophage-treated patients with Lower PD-L1 expression on peripheral blood monocytes at baseline LEXINGTON, Mass.--( BUSINESS WIRE )--Agenus Inc. (NASDAQ:AGEN), an immunology company developing innovative treatments for

LEXINGTON, Mass.--( BUSINESS WIRE )--Agenus Inc. (NASDAQ: AGEN), today announced additional details for the Company’s upcoming analyst and institutional investor meeting to be held on Thursday, May 14, 2015, from 4:30 to 6:30 PM Eastern Time in New York City.

Data simultaneously presented at ECCMID HZ/su vaccine achieves nearly 98% protection in people 70 or older This marks the second successful Phase 3 clinical program incorporating Agenus’ QS-21 Stimulon adjuvant LEXINGTON, Mass.--( BUSINESS WIRE )--Agenus Inc.

Final study results show significant reduction in malaria cases EMA currently reviewing the regulatory application LEXINGTON, Mass.--( BUSINESS WIRE )--Agenus Inc. (NASDAQ: AGEN), an immunology company developing innovative treatments for cancers and other diseases, announced today that final

Corporate Update Conference Call at 11 am ET Today Agenus to Host R&D Day in New York, NY on May 14 LEXINGTON, Mass.--( BUSINESS WIRE )--Agenus Inc. (NASDAQ:AGEN), an immunotherapy company developing immune-oncology checkpoint modulators (CPMs) and heat shock protein peptide-based vaccines as well

LEXINGTON, Mass.--( BUSINESS WIRE )--Agenus Inc. (NASDAQ: AGEN) will release its first quarter 2015 financial results before the market opens on Thursday, April 23, 2015. Agenus executives will host a conference call at 11 a.m. Eastern Time the same day.

SECANT® yeast display technology to provide speed and cost advantages Combination with Agenus’ mammalian Retrocyte DisplayTM technology to result in a uniquely powerful antibody platform LEXINGTON, Mass.--( BUSINESS WIRE )--Agenus Inc. (NASDAQ: AGEN) an immunology company developing innovative

Agenus to host conference call at 11 a.m. ET today LEXINGTON, Mass.--( BUSINESS WIRE )--Agenus Inc. (NASDAQ:AGEN), an immunology company developing novel therapeutic approaches based on checkpoint modulators (CPMs), heat shock protein-based vaccines, and immune adjuvants, today announced its

LEXINGTON, Mass.--( BUSINESS WIRE )--Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company developing a broad portfolio of checkpoint modulators (CPMs) and heat shock protein-based vaccines, as well as immune adjuvants, today announced that the Company will present at the Cowen and Company 35 th

LEXINGTON, Mass.--( BUSINESS WIRE )--Agenus Inc. (NASDAQ: AGEN), will release its fourth quarter and year end 2014 financial results before the market opens on Thursday, February 26, 2015. Agenus executives will host a conference call at 11 a.m. Eastern Time the same day.

LEXINGTON, Mass.--( BUSINESS WIRE )--Agenus Inc. (NASDAQ: AGEN), an immunology company developing a series of immune-oncology checkpoint modulators (CPMs), heat shock protein peptide-based vaccines, and immune adjuvants, today announced that the Company will present at the 17 th  Annual BIO CEO &

LEXINGTON, Mass.--( BUSINESS WIRE )--Agenus Inc. (Nasdaq: AGEN) will host a conference call today to discuss its global license, development and commercialization agreement with Incyte Corporation (Nasdaq: INCY) for novel immuno-oncology antibodies, which was announced earlier this morning.

Alliance to initially focus on four checkpoint modulator programs directed at GITR, OX40, TIM-3 and LAG-3 Incyte to have access to Agenus’ proprietary Retrocyte Display™ platform for the discovery of additional therapeutic antibodies Agenus to receive $60 million comprised of a $25 million

GSK’s ZOE-50 Phase 3 study meets primary endpoint of reducing the risk of shingles in people aged 50 and older Agenus is entitled to receive royalties on potential commercial sales of HZ/su LEXINGTON, Mass., Dec. 18, 2014 (GLOBE NEWSWIRE) -- Agenus Inc.

Agenus to host conference call beginning at 11 a.m. ET today LEXINGTON, Mass.--( BUSINESS WIRE )--Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a development pipeline of checkpoint modulators (CPMs), heat shock protein peptide-based vaccines, and adjuvants, today announced its